首页> 外文期刊>Pharmacological reviews >International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators
【24h】

International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators

机译:国际基础和临床药理学联盟。 XCVII。 G蛋白偶联的雌激素受体及其药理调节剂

获取原文
获取原文并翻译 | 示例
           

摘要

Estrogens are critical mediators of multiple and diverse physiologic effects throughout the body in both sexes, including the reproductive, cardiovascular, endocrine, nervous, and immune systems. As such, alterations in estrogen function play important roles in many diseases and pathophysiological conditions (including cancer), exemplified by the lower prevalence of many diseases in premenopausal women. Estrogens mediate their effects through multiple cellular receptors, including the nuclear receptor family (ER alpha and ER beta) and the G protein-coupled receptor (GPCR) family (GPR30/G protein-coupled estrogen receptor [GPER]). Although both receptor families can initiate rapid cell signaling and transcriptional regulation, the nuclear receptors are traditionally associated with regulating gene expression, whereas GPCRs are recognized as mediating rapid cellular signaling. Estrogen-activated pathways are not only the target of multiple therapeutic agents (e.g., tamoxifen, fulvestrant, raloxifene, and aromatase inhibitors) but are also affected by a plethora of phyto-and xeno-estrogens (e.g., genistein, coumestrol, bisphenol A, dichlorodiphenyltrichloroethane). Because of the existence of multiple estrogen receptors with overlapping ligand specificities, expression patterns, and signaling pathways, the roles of the individual receptors with respect to the diverse array of endogenous and exogenous ligands have been challenging to ascertain. The identification of GPER-selective ligands however has led to a much greater understanding of the roles of this receptor in normal physiology and disease as well as its interactions with the classic estrogen receptors ER alpha and ER beta and their signaling pathways. In this review, we describe the history and characterization of GPER over the past 15 years focusing on the pharmacology of steroidal and nonsteroidal compounds that have been employed to unravel the biology of this most recently recognized estrogen receptor.
机译:雌激素是男女在体内包括生殖,心血管,内分泌,神经和免疫系统在内的多种多样的生理作用的关键介质。因此,雌激素功能的改变在许多疾病和病理生理状况(包括癌症)中起着重要作用,例如,绝经前女性中许多疾病的患病率较低。雌激素通过多种细胞受体介导其作用,包括核受体家族(ERα和ERβ)和G蛋白偶联受体(GPCR)家族(GPR30 / G蛋白偶联雌激素受体[GPER])。尽管两个受体家族均可启动快速细胞信号传导和转录调控,但传统上核受体与调节基因表达有关,而GPCR被认为是介导快速细胞信号传导的媒介。雌激素激活的途径不仅是多种治疗药物(例如他莫昔芬,氟维司群,雷洛昔芬和芳香酶抑制剂)的靶标,而且还受到大量植物和异种雌激素(例如染料木黄酮,香豆酚,双酚A,二氯二苯基三氯乙烷)。由于存在多个具有重叠的配体特异性,表达模式和信号传导途径的雌激素受体,因此相对于内源性和外源性配体的多样化阵列,各个受体的作用难以确定。然而,对GPER选择性配体的鉴定使人们对该受体在正常生理和疾病中的作用以及与经典雌激素受体ERα和ERβ的相互作用及其信号传导途径有了更深入的了解。在这篇综述中,我们描述了过去15年中GPER的历史和特征,重点研究了甾体和非甾体化合物的药理作用,这些药物已被用来阐明这种最近公认的雌激素受体的生物学特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号